ARTICLE | Management Tracks
Ascidian names Abramson chief development officer
Plus: Layoffs at Leap claim 75% of staff and updates from Atalanta, Solu, Exagen
June 25, 2025 1:03 AM UTC
RNA exon editing company Ascidian Therapeutics Inc. named Murray Abramson chief development officer. Abramson was most recently SVP and head of clinical development at Precision Biosciences Inc. In 2011-20, he was VP of global clinical operations at Biogen Inc., where Ascidian founder, President and CEO Michael Ehlers was EVP and head of R&D.
Leap Therapeutics Inc. (NASDAQ:LPTX) said COO Augustine Lawlor and CMO Cyndi Sirard will be dismissed as part of a workforce reduction that will claim 75% of the company’s jobs. Leap is also winding down R&D operations, seeking partners for DKK1-targeting antibody sirexatamab and anti-GDF15 mAb FL-501, and exploring strategic options...